Patents by Inventor Ellen S. Yetzer

Ellen S. Yetzer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic composition
    Patent number: 8735345
    Abstract: Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: May 27, 2014
    Assignees: Hoffmann la Roche Inc., Pharmasset, Inc., Roche Palo Alto LLC
    Inventors: Steven B. Porter, Williamson Ziegler Bradford, Patrick F. Smith, Ellen S. Yetzer, Abel De La Rosa, Michael D. Rogers, William T. Symonds
  • COMBINATION OF A NUCLEOSIDE POLYMERASE INHIBITOR WITH A MACROCYCLIC PROTEASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF HEPATITIS C, LIVER FIBROSIS AND IMPAIRED LIVER FUNCTION (as amended)
    Publication number: 20120128628
    Abstract: Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof.
    Type: Application
    Filed: February 26, 2010
    Publication date: May 24, 2012
    Inventors: Steven B. Porter, Williamson Ziegler Bradford, Patrick F. Smith, Ellen S. Yetzer, Abel De La Rosa, Michael D. Rogers, William T. Symonds
  • THERAPEUTIC COMPOSITION
    Publication number: 20100221217
    Abstract: Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof.
    Type: Application
    Filed: February 26, 2010
    Publication date: September 2, 2010
    Applicants: InterMune, Inc., Roche Palo Alto LLC, Pharmasset, Inc.
    Inventors: Steven B. Porter, Williamson Ziegler Bradford, Patrick F. Smith, Ellen S. Yetzer, Abel De La Rosa, Michael D. Rogers, William T. Symonds